Vivos Therapeutics Inc. (VVOS)
Vivos Therapeutics Statistics
Share Statistics
Vivos Therapeutics has 5.89M shares outstanding. The number of shares has increased by 263.02% in one year.
| Shares Outstanding | 5.89M |
| Shares Change (YoY) | 263.02% |
| Shares Change (QoQ) | 1.47% |
| Owned by Institutions (%) | 0.33% |
| Shares Floating | 4.59M |
| Failed to Deliver (FTD) Shares | 15.65K |
| FTD / Avg. Volume | 6.11% |
Short Selling Information
The latest short interest is 95.09K, so 1.61% of the outstanding shares have been sold short.
| Short Interest | 95.09K |
| Short % of Shares Out | 1.61% |
| Short % of Float | 2.21% |
| Short Ratio (days to cover) | 0.66 |
Valuation Ratios
The PE ratio is -1.12 and the forward PE ratio is -2.93. Vivos Therapeutics's PEG ratio is 0.02.
| PE Ratio | -1.12 |
| Forward PE | -2.93 |
| PS Ratio | 1.1 |
| Forward PS | 1.1 |
| PB Ratio | 36.91 |
| P/FCF Ratio | -1.19 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Vivos Therapeutics Inc. has an Enterprise Value (EV) of 15.52M.
| EV / Earnings | -1.14 |
| EV / Sales | 1.12 |
| EV / EBITDA | -0.93 |
| EV / EBIT | -0.9 |
| EV / FCF | -1.22 |
Financial Position
The company has a current ratio of 0.34, with a Debt / Equity ratio of 4.85.
| Current Ratio | 0.34 |
| Quick Ratio | 0.34 |
| Debt / Equity | 4.85 |
| Total Debt / Capitalization | 82.92 |
| Cash Flow / Debt | -5.99 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -33.05% and return on capital (ROIC) is -718.87%.
| Return on Equity (ROE) | -33.05% |
| Return on Assets (ROA) | -1.27% |
| Return on Capital (ROIC) | -718.87% |
| Revenue Per Employee | $121,061.4 |
| Profits Per Employee | $-119,149.12 |
| Employee Count | 114 |
| Asset Turnover | 1.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -36.43% in the last 52 weeks. The beta is 7.43, so Vivos Therapeutics's price volatility has been higher than the market average.
| Beta | 7.43 |
| 52-Week Price Change | -36.43% |
| 50-Day Moving Average | 4.33 |
| 200-Day Moving Average | 3.09 |
| Relative Strength Index (RSI) | 41.97 |
| Average Volume (20 Days) | 256K |
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 13.8M and earned -13.58M in profits. Earnings per share was -11.14.
| Revenue | 13.8M |
| Gross Profit | 8.27M |
| Operating Income | -17.3M |
| Net Income | -13.58M |
| EBITDA | -16.68M |
| EBIT | -17.3M |
| Earnings Per Share (EPS) | -11.14 |
Balance Sheet
The company has 1.64M in cash and 2M in debt, giving a net cash position of -352K.
| Cash & Cash Equivalents | 1.64M |
| Total Debt | 2M |
| Net Cash | -352K |
| Retained Earnings | -93.05M |
| Total Assets | 15.35M |
| Working Capital | 2.27M |
Cash Flow
In the last 12 months, operating cash flow was -11.95M and capital expenditures -803K, giving a free cash flow of -12.75M.
| Operating Cash Flow | -11.95M |
| Capital Expenditures | -803K |
| Free Cash Flow | -12.75M |
| FCF Per Share | -10.46 |
Margins
Gross margin is 59.93%, with operating and profit margins of -125.32% and -98.42%.
| Gross Margin | 59.93% |
| Operating Margin | -125.32% |
| Pretax Margin | -98.42% |
| Profit Margin | -98.42% |
| EBITDA Margin | -120.82% |
| EBIT Margin | -125.32% |
| FCF Margin | -92.38% |
Dividends & Yields
VVOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -319.2% |
| FCF Yield | -62.03% |
Analyst Forecast
The average price target for VVOS is $6.3, which is 80.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.3 |
| Price Target Difference | 80.5% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 27, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Oct 27, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -9.28 |
| Piotroski F-Score | 4 |